ALK-Abelló A/S

Denmarkalk.net

ALK-Abelló A/S (ALK) is a Danish pharmaceutical company specializing in allergy immunotherapy. Headquartered in Hørsholm, Denmark, the company researches, develops, and manufactures biologically derived allergen products used to prevent and treat respiratory allergies. Its portfolio spans standardized sublingual immunotherapy tablets, subcutaneous immunotherapy formulations, and diagnostic extracts, as well as an adrenaline auto-injector for the emergency treatment of anaphylaxis.

ALK’s products target common allergens such as grasses, ragweed, house dust mites, and tree pollens. The company operates under rigorous quality and regulatory standards and supplies healthcare systems internationally through direct operations and partnerships. Its activities integrate R&D, clinical development, and GMP manufacturing, with a focus on scalable biologics production and global distribution to support evidence-based allergy care.

Also known as ALK-Abelló.

Latest news on ALK

5 February 2026
SPIE Advances ALK's Low-Carbon Transition at Vandeuil Plant

SPIE replaced gas boilers with heat pumps at ALK's Vandeuil site, cutting CO2 emissions by 305 tons annually and enhancing energy efficiency.